The treatment of tuberculosis

Respiration

Volumn 65, Issue 4, 1998, Pages 237-255

  Albino, Juan A ^a   Reichman, Lee B ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG MONITORING; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUBERCULOSIS;

EID: 0031695549     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029271     Document Type: Review

References (63)

1. Reichman LB: The U-shaped curve of concern. Am Rev Respir Dis 1991;144:741-742.
2. Reichman LB: How to ensure the continued resurgence of tuberculosis. Lancet 1996;347: 175-177.
3. Simone PM, Iseman MD: Drug-resistant tuberculosis: A deadly - and growing - danger. J Respir Dis 1992;13:960-971.
4. Reichman LB: Tuberculosis elimination - What's to stop us? Int J Tuberc Lung Dis 1997; 1:3-11.
5. Herzog H: History of tuberculosis. Respiration 1998;65:5-15.
6. Brändli O: The clinical presentation of tuberculosis. Respiration 1998;65:87-105.
7. Gangadharam PRJ: Drug resistance in tuberculosis; in Reichman LB, Hershfield ES (eds): Tuberculosis: A Comprehensive International Approach. New York, Dekker, 1993, pp 293-328.
8. Toman K: Tuberculosis: Case-Finding and Chemotherapy, Questions and Answers. Geneva, World Health Organization, 1979.
9. Heifets L: Mycobacteriology laboratory. Clin Chest Med 1997;1:35-54.
10. Frieden TR, Woodley CL, Crawford JT, Lew D, Dooley SM: The molecular epidemiology of tuberculosis in New York City: The importance of nosocomial transmission and laboratory error. Tuber Lung Dis 1996;77:407-413.
11. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN: Outcome of MDR-TB patients, 1983-1993. Am J Respir Crit Care Med 1996; 153:317-324.
12. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al: Global surveillance for antituberculous-drug resistance, 1994-1997. N Engl J Med 1998;338: 1641-1649.
13. Centers for Disease Control and Prevention: Core Curriculum on Tuberculosis: What the clinician should know, ed 3. Atlanta, Centers for Disease Control and Prevention, 1994.
14. Davis AL: History of the sanatorium movement; in Rom WN, Garay S (eds): Tuberculosis. Boston, Little, Brown, 1996, pp 35-54.
15. Centers for Disease Control and Prevention: Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1993; 42(No. RR-7):1-8.
16. Small PM, Schecter GF, Goodman PC, et al: Treatment of tuberculosis in patients with advanced human immunodeficiency virus. N Engl J Med 1991;324:289-294.
17. Perriens JH, St. Louis ME, Mukadi YB: Pulmonary tuberculosis in HIV-infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332: 779-784.
18. Pulido F, Pena JM, Rubio R: Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997;157:227-232.
19. Moulding T, Dutt AK, Reichman LB: Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995;122:951-954.
20. Gillespie SH, Kennedy N: Fluoroquinolones: A new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-271.
21. McGregor MM, Olliaro P, Wolmarans L, et al: Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154:1462-1467.
22. Dhillon J, Mitchison DA: Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992;145:212-214.
23. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, et al: Effectiveness of rifampin, rifabutin, and rifapentine for the preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148:1541-1546.
24. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-1374.
25. Andrew OT, Schonfeld PY, Hopewell PC, Humphreys MH: Tuberculosis in patients with end-stage renal disease. Am J Med 1980;68: 59-65.
26. Ellard GA: Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993;64:169-181.
27. Anderson GD: Tuberculosis in pregnancy. Semin Perinatol 1997;21:328-335.
28. Brost BC, Newman RB: The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am 1997;24:659-663.
29. Dossing M, Wilcke DS, Askgaard S, Nybo B: Liver injury during antituberculous treatment: An 11-year study. Tuber Lung Dis 1996;77: 335-340.
30. Vasudeva R, Woods B: Isoniazid-related hepatitis. Dig Dis 1997;15:357-367.
31. Peloquin CA: Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.
32. Strayhorn VA, Baciewicz AM, Self TH: Update on rifampin drug interactions III. Arch Intern Med 1997;157:2453-2458.
33. Centers for Disease Control and Prevention: Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculous patients with rifampin. MMWR Morb Mortal Wkly Rep 1996;45:921-925.
34. Case Record of the Massachusetts General Hospital (case 3-1998). N Engl J Med 1998; 338:248-254.
35. Aquinas M, Allan WG, Horsfall PA, Jenkins PK, Hung-Yan W, et al: Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972;i(803):765-771.
36. Matz J, Borish LC, Routes JM, Rosenwasser LJ: Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994;149:815-817.
37. Frieden TR, Sterling T, Pablos-Mendez A, et al: The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328: 521-526.
38. Moore M, Onarato IM, Mccray E, Castro KG: Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997;278: 833-837.
39. World Health Organization Global Tuberculosis Programme: Anti-tuberculous drug resistance in the world. Geneva, WHO, 1997.
40. Weiss SE, Slocum PC, Biais FX, et al: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184.
41. Crofton J, Chaulet P, Maher D: Guidelines for the Management of Drug-Resistant Tuberculosis. Geneva, World Health Organization, 1997.
42. Iseman MD: Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-791.
43. Bureau of Tuberculosis Control: Clinical Policies and Protocols, ed 2. New York, New York City Department of Health, 1977.
44. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-532.
45. Castro KG, Snider DE: The good news and the bad news about multidrug-resistant tuberculosis (editorial). Clin Infect Dis 1995;21:1265-1266.
46. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, Fazal BA: Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21:1238-1244.
47. Telzak EE, Sipkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr E, Blum S, Gagliardi A, Salomon N, Turett G: Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-911.
48. Maher D, Chaulet P, Spinaci S, Harries A: Treatment of Tuberculosis Guidelines for National Programmes, ed 2. Geneva, World Health Organization, 1997.
49. Centers for Disease Control and Prevention: Essential components of a tuberculosis prevention and control program. MMWR Morb Mortal Wkly Rep 1995;44:1-16.
50. Centers for Disease Contol and Prevention: Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities. MMWR Morb Mortal Wkly Rep 1994; 13(No. RR-13):1-123.
51. Bock NN, McGowan JE, Ahn J, Tapia J, Blumberg HM: Clinical predictors of tuberculosis as a guide for a respiratory isolation policy. Am J Respir Crit Care Med 1996;154:1468-1472.
52. Elsolh A, Mylotte J, Sherif S, Serghani J, Grant BJB: Validity of a clinical decision tree for predicting active pulmonary tuberculosis. Am J Respir Crit Care Med 1997;155:1711-1716.
53. Nardell EA: Needles in haystacks: Diagnosing tuberculosis under low prevalence conditions. Tuber Lung Dis 1996;77:389-390.
54. Wurtz R: Administrative controls for TB: Keep doing what you've always done, and you'll get what you always got. Infection Control Hosp Epidemiol 1996;17:409-411.
55. Harries AD, Mahler D: Tuberculosis and HIV: A Clinical Manual. Geneva, World Health Organization, 1996.
56. Hasley NA, Coberly JS, Desormeaux J, Losikoff P, et al: Randomized trial of isoniazid versus rifampin and pyrazinamide for the prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
57. National Institute of Allergy and Infectious Diseases Press Release: Short-course TB prophylaxis effective in HIV-infected individuals. National Institutes of Health at website: niaid.nih.gov/newsroom/tb2.htm, February 11, 1998.
58. Castelo A, Mathiasi PA, Iunes R, et al: Cost effectiveness of antituberculosis interventions. Pharmacoeconomics 1995;8:385-399.
59. Moore RD, Chaulk CP, Cavalcante S, Chaisson RE: Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154(Pt 1): 1013-1019.
60. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR: A cost-effectiveness analysis of directly observed therapy for treatment of tuberculosis. Chest 1997;112:663-670.
61. Floyd K, Wilkinson D, Gilks C: Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis - Experience from rural South Africa. BMJ 1997;315:1407-1411.
62. Mahmoudi A, Iseman MD: Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993;270:147-149.
63. Sumartojo EM, Geiter LJ, Miller B, Hale BE: Can physicians treat tuberculosis - Report on a national survey of physicians practices. Am J Publ Health 1997;87:2008-2011.